{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-141380","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.405730+00:00","generated_at":"2026-06-15T04:08:20.798573+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galera Therapeutics Q1 net loss $17.7M; avasopasem NDA gets FDA priority review with PDUFA Aug 9","bullets":["Net loss of $17.7M ($0.50 per share) in Q1 2023 vs $15.4M ($0.58 per share) in Q1 2022.","Cash, cash equivalents and short-term investments of $47.8M as of March 31, 2023; expected to fund operations into Q4 2023.","FDA granted priority review for avasopasem NDA for radiotherapy-induced severe oral mucositis; PDUFA date August 9, 2023.","Raised $30M gross proceeds from registered direct offering in February 2023.","Expanded commercial leadership team with three new VPs in preparation for potential U.S. launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-141380","json":"https://secwatch.observer/filing/0001193125-23-141380.json","markdown":"https://secwatch.observer/filing/0001193125-23-141380.md","text":"https://secwatch.observer/filing/0001193125-23-141380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/0001193125-23-141380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/d476140d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:08:20.798573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ba5478cff948ca9b5c72ca919740b312e31f309","claim":"Galera Therapeutics, Inc. reported financial results for quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Galera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312523141380/0001193125-23-141380-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}